prikaz prve stranice dokumenta Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients
  Download
PDF 205.53 KB
Scientific paper - Original scientific paper
Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients
Croatian Medical Journal, 56 (2015), 3; 263-271. https://doi.org/10.3325/cmj.2015.56.263
Batinić, Josip; Perić, Zinaida; Šegulja, Dragana; Last, James; Prijić, Sanja; Dubravčić, Klara; Volarić, Lidija; Sertić, Dubravka; Radman, Ivo; Bašić-Kinda, Sandra; Matišić, Danica; Batinić, Drago; Labar, Boris; Nemet, Damir

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Batinić, J., Perić, Z., Šegulja, D., Last, J., Prijić, S., Dubravčić, K. ... Nemet, D. (2015). Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients. Croatian Medical Journal, 56. (3), 263-271. doi: 10.3325/cmj.2015.56.263

Batinić, Josip, et al. "Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients." Croatian Medical Journal, vol. 56, no. 3, 2015, pp. 263-271. https://doi.org/10.3325/cmj.2015.56.263

Batinić, Josip, Zinaida Perić, Dragana Šegulja, James Last, Sanja Prijić, Klara Dubravčić, Lidija Volarić, et al. "Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients." Croatian Medical Journal 56, no. 3 (2015): 263-271. https://doi.org/10.3325/cmj.2015.56.263

Batinić, J., et al. (2015) 'Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients', Croatian Medical Journal, 56(3), pp. 263-271. doi: 10.3325/cmj.2015.56.263

Batinić J, Perić Z, Šegulja D, Last J, Prijić S, Dubravčić K, and sur.. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients. Croatian Medical Journal [Internet]. 2015 June [cited 2024 November 27];56(3):263-271. doi: 10.3325/cmj.2015.56.263

J. Batinić, et al., "Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients", Croatian Medical Journal, vol. 56, no. 3, pp. 263-271, June 2015. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:200701. [Accessed: 27 November 2024]

Metadata
Title (english)Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients
AuthorJosip Batinić
AuthorZinaida Perić
AuthorDragana Šegulja
AuthorJames Last
AuthorSanja Prijić
AuthorKlara Dubravčić
AuthorLidija Volarić
AuthorDubravka Sertić
AuthorIvo Radman
AuthorSandra Bašić-Kinda
AuthorDanica Matišić
AuthorDrago Batinić
AuthorBoris Labar
AuthorDamir Nemet
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
AIM: To evaluate the clinical utility of incorporating a novel heavy/light chain immunoassay (HLC) into the existing methods for the assessment of multiple myeloma (MM) patients. ----- METHODS: Convenience sera samples from 90 previously treated IgG and IgA MM patients in different disease stages were analyzed. The study was conducted in Clinical Hospital Center Zagreb between 2011 and 2013. The collected sera were analyzed by standard laboratory techniques (serum protein electrophoresis, quantification of total immunoglobulins, serum immunofixation, serum free light chain [FLC] assay) and HLC assay. ----- RESULTS: HLC ratios outside the normal range were found in 58 of 90 patients, including 28 out of 61 patients with total immunoglobulin measurements within the normal range and 5 out of 23 patients in complete response. Both elevated HLC isotype level and abnormal HLC ratio correlated with the parameters of tumor burden, including percentage of plasma cells in the bone marrow (P<0.001 and P=0.002, respectively) and an abnormal serum FLC ratio (for both P<0.001). In addition, abnormal HLC isotype level correlated with serum beta-2-microglobulin level (P=0.038). In terms of prognosis, abnormal HLC isotype level and abnormal HLC ratio were significantly associated with shorter overall survival (P<0.001 and P=0.002, respectively). Interestingly, suppression of the uninvolved (polyclonal) isotype pair, but not other non-myeloma immunoglobulin isotypes, was also associated with a shorter overall survival (P=0.021). In a multivariate analysis, an abnormal HLC ratio and β2-microglobulin level >3.5mg/L were independent risk factors for survival. ----- CONCLUSION: The new HLC assay has greater sensitivity in detecting monoclonal protein, correlates with tumor burden markers, and affects patients' outcome.
Abstract (croatian)
Analiza teških/lakih lanaca imunoglobulina olakšava otkrivanje rezidualne bolesti i praćenje pacijenata s multiplim mijelomom ----- Cilj: Odrediti kliničku korisnost uključivanja novog imunoeseja za određivanje razine omjera teških/lakih lanaca (prema engl. heavy/light chain, HLC) u postojeći skup metoda za procjenu stanja pacijenata s multiplim mijelomom (MM). ----- Postupci: Analizirali smo uzorke seruma 90 pacijenata u različitim fazama bolesti koji su ranije liječeni zbog IgG i IgA MM. Istraživanje je provedeno u Kliničko-bolničkom Centru „Zagreb“ između 2011. i 2013. Uzorci su analizirani standardnim laboratorijskim metodama (elektroforeza serumskih proteina, određivanje ukupnih immunoglobulina, imunofiksacija u serumu, određivanje serumskih slobodnih lakih lanaca) i određivanjem razine HLC. ----- Rezultati: 58 od 90 pacijenata imalo je omjer HLC koji odstupa od normalnih vrijednosti, uključujući i 28 od 61 pacijenta s normalnim vrijednostima ukupnih imunoglobulina i 5 od 23 pacijenta sa potpunim odgovorom. Povišena razina izotipova HLC i omjer HLC izvan normalnih vrijednosti korelirali su s parametrima tumorskog opterećenja, uključujući postotak plazma stanica u koštanoj srži (P < 0,001 odnosno P = 0,002) i omjer serumskih slobodnih lakih lanaca koji odstupa od normalnih vrijednosti (P < 0,001 za obje korelacije). Razina izotipova HLC koja odstupa od normalnih vrijednosti korelirala je sa razinom serumskih β2-mikroglobulina (P = 0,038). Što se tiče prognoze, razina izotipova HLC koja odstupa od normalnih vrijednosti i omjer HLC koji odstupa od normalnih vrijednosti bili su značajno povezani s kraćim ukupnim preživljenjem (P < 0,001 odnosno P = 0,002). Zanimljivo je da je supresija neuključenog (poliklonalnog) izotipnog para, ali ne i drugih nemijelomskih imunoglobulinskih izotipova, također bila povezana s kraćim ukupnim preživljenjem (P = 0,021). Multivarijatna analiza pokazala je da su omjer HLC koji odstupa od normalnih vrijednosti i razina β2-mikroglobulina >3,5 mg/L neovisni čimbenici rizika za preživljenje. ----- Zaključak: Novi imunoesej za mjerenje HLC ima veću osjetljivost za utvrđivanje monoklonalnih proteina, korelira s biljezima tumorskog opterećenja i predviđa ishod bolesti kod pacijenta.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCroatian Medical Journal
Numberingvol. 56, no. 3, pp. 263-271
p-ISSN0353-9504
DOIhttps://doi.org/10.3325/cmj.2015.56.263
URN:NBNurn:nbn:hr:105:200701
Publication2015-06
Document URLhttps://doi.org/10.3325/cmj.2015.56.263
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:27:13